Page 1

CRISPRI THERAPEUTICS CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results -Achieved target enrollment in CTX001 clinical trials for beta thalassemia ( TDT ) and sickle cell disease ( SCD ) ; regulatory submissions planned for late 2022 -Reported positive results from the ongoing Phase 1 CARBON clinical trial evaluating the safety and efficacy of CTX110 for CD19 + B - cell malignancies ; enrollment continues , with potential registrational trial incorporating consolidation dosing expected to initiate in Q1 2022 -Implementing consolidation dosing protocols for CTX120TM and CTX130TM clinical trials ; enrollment continues , with top - line data expected to report in 1H 2022 -Regenerative medicine and in vivo programs continue to progress and remain on track ZUG , Switzerland and CAMBRIDGE , Mass . , November 3 , 2021 - CRISPR Therapeutics ( Nasdaq : CRSP ) , a biopharmaceutical company focused on creating transformative gene - based medicines for serious diseases , today reported financial results for the third quarter ended September 30 , 2021 . " The third quarter marked significant progress across our portfolio , " said Samarth Kulkarni , Ph.D. , Chief Executive Officer of CRISPR Therapeutics . " With our partner Vertex , we achieved target enrollment for the CTX001 clinical trials in patients with beta thalassemia and sickle cell disease , which can support regulatory submissions in late 2022. Additionally , we demonstrated proof of concept for our allogeneic CAR - T platform with positive data from our CARBON trial of CTX110 , which showed that immediately available " off - the - shelf " cell therapies can offer efficacy similar to autologous CAR - T with a differentiated safety profile for patients with large B - cell lymphomas . Based on these encouraging results , we plan to expand the CARBON trial into a potentially registrational trial in the first quarter of 2022. Furthermore , we hope to bring these transformative allogeneic CAR - T therapies to patients in outpatient and community oncology settings , enabling broad access . " Recent Highlights and Outlook Beta Thalassemia and Sickle Cell Disease O Data presented to date for 22 patients with greater than 3 months of follow - up support the profile of CTX001 as a one - time functional cure for patients with TDT and severe SCD , showing consistent and durable benefit across all treated patients . Target enrollment has been achieved in the ongoing clinical trials for CTX001 in TDT and SCD , with planned regulatory submissions in late 2022 . Immuno - Oncology